![TAK-285 Size:Solid 10 mg Smiles: CC(N[C@@H]1C[C@H]1C1C=CC=CC=1)C1=CC2OCCOC=2C=C1](https://cdn.shopify.com/s/files/1/0389/1897/9723/products/M10290_1621561641.gif?v=1621561643)
Pay in 4 interest-free payments of $23.75 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
Smiles: CC(N[C@@H]1C[C@H]1C1C=CC=CC=1)C1=CC2OCCOC=2C=C1
2019 May 3
Dainichi T
71(15):5057-61
Bivalirudin overcomes many limitations seen with indirect thrombin inhibitors
TAK-285 Size:Solid 10 mg Smiles: CC(N[C@@H]1C[C@H]1C1C=CC=CC=1)C1=CC2OCCOC=2C=C1TAK 285 is a novel dual erbB protein kinase inhibitor that specifically targets human epidermal growth factor receptor (EGFR) and HER2. Methods: TAK 285 is currently being developed by Takeda. TAK 285 was found to be well tolerate in Phase I trials. Absorption of TAK 285 was rapid after oral dosing, and plasma exposure at steady state increased in a dose proportional fashion for doses ranging from 50 to 300 mg b. i. d. A partial response was observed
US$ 2447.52
US$ 39.99
US$ 303.04